
|Articles|March 15, 2006
SCORE investigators update, expand enrollment criteria
Madison, WI?Investigators expanded the eligibility criteria of the SCORE study, a multicenter, randomized clinical trial designed to investigate the safety and efficacy of standard care versus intravitreal triamcinolone acetonide (IVTA) injections for the treatment of macular edema associated with central and branch retinal vein occlusion. The broader standards will accommodate a patient population more closely matched to those seen in the practice setting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
2
4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region
3
AAVantgarde Bio closes $141 million Series B financing round
4
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
5


















































.png)


